AbbVie Trying Its Hand At All-In-One Screwdriver CAR-T Cancer Immunotherapy [Seeking Alpha]
Cellectis S.A. - American Depositary Shares (CLLS)
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cellectis.com/en/investors
Company Research
Source: Seeking Alpha
Summary CAR-T technology seems to be evolving and progressing faster than smartphones, at least in theoretical prototypes if not actual treatments. The latest exciting move comes from AbbVie ( ABBV ), which is moving to the CAR-T space in a licensing partnership with the California Institute for Biomedical Research, a.k.a. Calibr. In my previous piece on CAR-T developments, we covered Cellectis ( CLLS ) and its CubiCAR concept, which removes antigens from the T-cell and only carries the antigen engineered to make the T-cell recognize and attack cancer. In addition, CubiCAR contains an on-off switch sensitive to Roche's ( OTCQX:RHHBY ) Rituxan, which functions as an on/off switch in the event of severe life-threatening side effects, which are actually quite common with CAR-T. Removal of other antigens allows for a potentially off-the-shelf product because it removes immunogenicity, or the activation of an immune response, which addresses cost issues. The off switch address
Show less
Read more
Impact Snapshot
Event Time:
CLLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLLS alerts
High impacting Cellectis S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CLLS
News
- Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs [Yahoo! Finance]Yahoo! Finance
- Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsGlobeNewswire
- SmartCella strengthens team with Dr Ricardo Baptista as CTO [Yahoo! Finance]Yahoo! Finance
- Cellectis S.A. (NASDAQ: CLLS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs [Yahoo! Finance]Yahoo! Finance
CLLS
Earnings
- 11/6/23 - In-Line
CLLS
Sec Filings
- 4/22/24 - Form 6-K
- 4/10/24 - Form 6-K
- 4/8/24 - Form 6-K
- CLLS's page on the SEC website